◎ Sugi Atlas

Atlas / Disease / Neurotic disorder

Neurotic disorder

disease
On this page

Also known as depressive neurosisdisorder, neuroticdisorders, neuroticneurosesneurosisneurotic depressionneurotic depression reactive typeneurotic depressive statePsychoneurosespsychoneurosis NOSreactive depression

Summary

Neurotic disorder (MONDO:0005379) is a disease with 7 cohort genes (72 GWAS associations across 10 studies) and 6 clinical trials. Top therapeutic interventions include lamotrigine.

At a glance

  • Cohort genes: 7
  • GWAS associations: 72
  • Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameneurotic disorder
Mondo IDMONDO:0005379
EFOEFO:0004257
MeSHD009497
DOIDDOID:4964
NCITC34848
SNOMED CT111475002
UMLSC0027932
MedGen10334
Is cancer (heuristic)no

Also known as: depressive neurosis · disorder, neurotic · disorders, neurotic · neuroses · neurosis · neurotic depression · neurotic depression reactive type · neurotic depressive state · neurotic disorder · Psychoneuroses · psychoneurosis NOS · reactive depression

Data availability: 72 GWAS associations (10 studies).

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › anxiety disorder › neurotic disorder

Related subtypes (9): separation anxiety disorder, neurocirculatory asthenia, generalized anxiety disorder, phobic disorder, acute stress disorder, panic disorder, obsessive-compulsive disorder, anxiety, mixed anxiety and depressive disorder

Subtypes (1): post-traumatic stress disorder

Genetics & variants

GWAS landscape

72 GWAS associations across 10 studies. Top hits map to 37 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs620622887e-22MAPTA0.02
rs29210363e-20LINC02950 - RN7SL178PT0.02
rs112501173e-19XKR6A0.02
rs116650703e-16CELF4 - MIR4318G0.02
rs357385854e-16DRD2 - TMPRSS5G0.02
rs4778606e-14MIR124-1HG - MSRA-DTT0.01
rs101448454e-13YLPM1C0.01
rs22694263e-12TNXBA0.01
rs71073565e-12MTCH2 - AGBL2A0.01
rs20425555e-12RNA5SP106 - ACVR2AA0.01
rs110900451e-11ZC3H7BA0.01
rs108966363e-11ZDHHC5G0.01
rs20717544e-11PAX6C0.01
rs41407994e-11SIPA1L1G0.01
rs132268416e-11GRM8C0.01
rs78455157e-11CSMD1 - SNORA70A0.01
rs44135181e-10FBXL17 - LINC01023A0.01
rs560841681e-10BAIAP2, AATKT0.01
rs115098802e-10TMEM106BA0.01
rs15422124e-10ARPP21G0.01
rs37414754e-10NOS1A0.01
rs564034214e-10CCDC68 - LINC01929C0.01
rs22786096e-10PLCL2C0.01
rs116083557e-10MYO1HC0.01
rs10026568e-10FTLP18 - GRIK3C0.01
rs109351841e-09STAG1C0.01
rs22109031e-09ZDHHC20P4 - SNRPFP3G0.01
rs129035631e-09LINGO1T0.01
rs2746322e-09SOCS5P1 - GRM3A0.01
rs283772682e-09PTCH1T0.01

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST001771Aragam N20122,7480TMPRSS9 and GRIN2B are associated with neuroticism: a genome-wide association study in a European sample.
GCST90473283UK Biobank Whole-Genome Sequencing Consortium20251,100457,340Whole-genome sequencing of 490,640 UK Biobank participants.
GCST000063Shifman S20071,0381,016A whole genome association study of neuroticism using DNA pooling.
GCST90246060Walters RG202315275,748Genotyping and population characteristics of the China Kadoorie Biobank.
GCST90726774Kim HI202612743,899Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST010017Cai N202000Minimal phenotyping yields genome-wide association signals of low specificity for major depression.
GCST90029028Loh PR201800Mixed-model association for biobank-scale datasets.
GCST000724Calboli FC201000A genome-wide association study of neuroticism in a population-based sample.
GCST004569Calboli FC201000A genome-wide association study of neuroticism in a population-based sample.
GCST000226van den Oord EJ200800Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic49

MAF distribution

BucketVariants
common (>=0.05)50
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant36
intergenic_variant12
3_prime_UTR_variant1
synonymous_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs620622881746019187G>A0.218intron_variantMAPT7e-22Tier 4: intronic/intergenic
rs292103688506387T>C0.49intergenic_variantLINC02950 - RN7SL178P3e-20Tier 4: intronic/intergenic
rs11250117811115230C>A,G0.467intron_variantXKR63e-19Tier 4: intronic/intergenic
rs116650701837572600G>A0.331intron_variantCELF4 - MIR43183e-16Tier 4: intronic/intergenic
rs3573858511113515625T>G0.433intergenic_variantDRD2 - TMPRSS54e-16Tier 4: intronic/intergenic
rs47786089954255T>A,C0.297intron_variantMIR124-1HG - MSRA-DT6e-14Tier 4: intronic/intergenic
rs101448451474771067C>G,T0.317intron_variantYLPM14e-13Tier 4: intronic/intergenic
rs2269426632108722G>A,C,T0.359intron_variantTNXB3e-12Tier 4: intronic/intergenic
rs71073561147654618A>G,T0.494intergenic_variantMTCH2 - AGBL25e-12Tier 4: intronic/intergenic
rs20425552147797920G>A,T0.418intergenic_variantRNA5SP106 - ACVR2A5e-12Tier 4: intronic/intergenic
rs110900452241357599G>A,C0.3033_prime_UTR_variantZC3H7B1e-11Tier 2: splice/UTR
rs108966361157680560C>G0.345intron_variantZDHHC53e-11Tier 4: intronic/intergenic
rs20717541131791034C>G,T0.201intron_variantPAX64e-11Tier 4: intronic/intergenic
rs41407991471704252G>A0.47intron_variantSIPA1L14e-11Tier 4: intronic/intergenic
rs132268417126749354T>A,C,G0.49intron_variantGRM86e-11Tier 4: intronic/intergenic
rs784551585088706G>A,C0.287intergenic_variantCSMD1 - SNORA707e-11Tier 4: intronic/intergenic
rs44135185108402300G>A,C0.219intron_variantFBXL17 - LINC010231e-10Tier 4: intronic/intergenic
rs560841681781110774C>A,T0.148intron_variantBAIAP2, AATK1e-10Tier 4: intronic/intergenic
rs11509880712222285G>A,C,T0.328intron_variantTMEM106B2e-10Tier 4: intronic/intergenic
rs1542212335642443T>C,G0.392intron_variantARPP214e-10Tier 4: intronic/intergenic
rs374147512117232109G>A,C0.194synonymous_variantNOS14e-10Tier 4: intronic/intergenic
rs564034211855098052A>C,T0.331intron_variantCCDC68 - LINC019294e-10Tier 4: intronic/intergenic
rs2278609316882947C>A,G,T0.216intron_variantPLCL26e-10Tier 4: intronic/intergenic
rs1160835512109441487T>C0.313intron_variantMYO1H7e-10Tier 4: intronic/intergenic
rs1002656136727140C>T0.29intergenic_variantFTLP18 - GRIK38e-10Tier 4: intronic/intergenic
rs109351843136434626T>C,G0.409intron_variantSTAG11e-09Tier 4: intronic/intergenic
rs22109031369002843G>A,C,T0.369intergenic_variantZDHHC20P4 - SNRPFP31e-09Tier 4: intronic/intergenic
rs129035631577741393T>C0.48intergenic_variantLINGO11e-09Tier 4: intronic/intergenic
rs274632786639865C>A0.423intergenic_variantSOCS5P1 - GRM32e-09Tier 4: intronic/intergenic
rs28377268995462774G>A,C,T0.107intron_variantPTCH12e-09Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
GPC6Orphanet:93329Autosomal recessive omodysplasia
PDE4DOrphanet:439822PDE4D haploinsufficiency syndrome
PDE4DOrphanet:950Acrodysostosis

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only7

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
NKAIN2HGNC:16443ENSG00000188580Q5VXU1Sodium/potassium-transporting ATPase subunit beta-1-interacting protein 2gwas
MDGA2HGNC:19835ENSG00000139915Q7Z553MAM domain-containing glycosylphosphatidylinositol anchor protein 2gwas
NXPH1HGNC:20693ENSG00000122584P58417Neurexophilin-1gwas
ARRDC4HGNC:28087ENSG00000140450Q8NCT1Arrestin domain-containing protein 4gwas
TMPRSS9HGNC:30079ENSG00000178297Q7Z410Transmembrane protease serine 9gwas
GPC6HGNC:4454ENSG00000183098Q9Y625Glypican-6gwas
PDE4DHGNC:8783ENSG00000113448Q084993’,5’-cyclic-AMP phosphodiesterase 4Dgwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
MDGA2MAM domain-containing glycosylphosphatidylinositol anchor protein 2May be involved in cell-cell interactions.
NXPH1Neurexophilin-1May be signaling molecules that resemble neuropeptides and that act by binding to alpha-neurexins and possibly other receptors.
ARRDC4Arrestin domain-containing protein 4Functions as an adapter recruiting ubiquitin-protein ligases to their specific substrates.
TMPRSS9Transmembrane protease serine 9Serase-1 and serase-2 are serine proteases that hydrolyze the peptides N-t-Boc-Gln-Ala-Arg-AMC and N-t-Boc-Gln-Gly-Arg-AMC.
GPC6Glypican-6Cell surface proteoglycan that bears heparan sulfate.
PDE4D3’,5’-cyclic-AMP phosphodiesterase 4DHydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.

Protein-family classification

Druggable: 3 · Difficult: 0 · Unknown: 4 · Druggable fraction: 0.43

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Protease15.2×0.433
Antibody/Immunoglobulin14.2×0.433
Enzyme (other)11.7×0.609
Other/Unknown41.0×0.626

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
NKAIN2Other/UnknownnoNa/K-Atpase_Interacting
MDGA2Antibody/ImmunoglobulinyesMAM_dom, Ig_sub2, Ig_sub
NXPH1Other/UnknownnoNxph, NXPH/NXPE
ARRDC4Other/UnknownnoArrestin-like_N, Arrestin-like_C, Arrestin-like_C_sf
TMPRSS9ProteaseyesTrypsin_dom, Peptidase_S1A, LDrepeatLR_classA_rpt
GPC6Other/UnknownnoGlypican, Glypican_CS
PDE4DEnzyme (other)yes3.1.4.53PDEase_catalytic_dom, PDEase, PDEase_CS

Expression context

Cohort genes with no expression data: 0.

7 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)7
unknown0

Top tissues across cohort

TissueCohort genes
C1 segment of cervical spinal cord1
corpus callosum1
spinal cord1
cortical plate1
male germ line stem cell (sensu Vertebrata) in testis1
primordial germ cell in gonad1
endothelial cell1
right adrenal gland1
right adrenal gland cortex1
skin of hip1
upper arm skin1
upper leg skin1
liver1
right lobe of liver1
right testis1
cartilage tissue1
tibia1
vena cava1
biceps brachii1
gluteal muscle1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
NKAIN2178broadmarkerC1 segment of cervical spinal cord, spinal cord, corpus callosum
MDGA285broadmarkercortical plate, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad
NXPH195tissue_specificmarkerright adrenal gland cortex, endothelial cell, right adrenal gland
ARRDC4255ubiquitousmarkerupper leg skin, upper arm skin, skin of hip
TMPRSS9128tissue_specificmarkerright lobe of liver, liver, right testis
GPC6217ubiquitousmarkercartilage tissue, tibia, vena cava
PDE4D283ubiquitousmarkergluteal muscle, biceps brachii, skeletal muscle tissue of rectus abdominis

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
NXPH11,931
PDE4D1,533
MDGA21,351
NKAIN21,271
GPC61,237
ARRDC4877
TMPRSS9509

Intra-cohort edges

ABSources
MDGA2PDE4Dstring_interaction

Structural data

PDB: 1 · AlphaFold-only: 6 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
PDE4DQ08499122

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
MDGA2Q7Z55384.96
GPC6Q9Y62582.67
ARRDC4Q8NCT180.38
NKAIN2Q5VXU176.15
TMPRSS9Q7Z41074.96
NXPH1P5841767.14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 22. Enrichment computed across 7 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Defective EXT2 causes exostoses 21271.9×0.014GPC6
Defective EXT1 causes exostoses 1, TRPS2 and CHDS1271.9×0.014GPC6
Attachment and Entry1200.3×0.014GPC6
Defective B4GALT7 causes EDS, progeroid type1190.3×0.014GPC6
Defective B3GAT3 causes JDSSDHD1190.3×0.014GPC6
Defective B3GALT6 causes EDSP2 and SEMDJL11190.3×0.014GPC6
HS-GAG degradation1165.5×0.014GPC6
Respiratory syncytial virus (RSV) attachment and entry1165.5×0.014GPC6
DARPP-32 events1158.6×0.014PDE4D
Initiation of coagulation cascade1158.6×0.014GPC6
Glycosaminoglycan-protein linkage region biosynthesis1131.3×0.015GPC6
Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells1119.0×0.015PDE4D
HS-GAG biosynthesis1115.3×0.015GPC6
Dengue Virus Attachment and Entry186.5×0.018GPC6
Retinoid metabolism and transport182.8×0.018GPC6
Regulation of clotting cascade177.7×0.018GPC6
Post-translational modification: synthesis of GPI-anchored proteins156.0×0.023MDGA2
RSV-host interactions152.1×0.023GPC6
G alpha (s) signalling events124.4×0.047PDE4D
Dengue Virus-Host Interactions115.2×0.071GPC6
Post-translational protein modification16.4×0.155MDGA2
Metabolism of proteins14.1×0.223MDGA2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
extracellular vesicle biogenesis11203.7×0.014ARRDC4
negative regulation of relaxation of cardiac muscle11203.7×0.014PDE4D
negative regulation of heart contraction1601.9×0.015PDE4D
positive regulation of ubiquitin-protein transferase activity1300.9×0.015ARRDC4
cAMP catabolic process1267.5×0.015PDE4D
adrenergic receptor signaling pathway1267.5×0.015PDE4D
regulation of cell communication by electrical coupling involved in cardiac conduction1267.5×0.015PDE4D
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway1240.7×0.015PDE4D
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel1240.7×0.015PDE4D
positive regulation of interleukin-5 production1200.6×0.015PDE4D
plasminogen activation1185.2×0.015TMPRSS9
cellular response to epinephrine stimulus1185.2×0.015PDE4D
regulation of cardiac muscle cell contraction1160.5×0.016PDE4D
regulation of sodium ion transport1133.8×0.016NKAIN2
spinal cord motor neuron differentiation1133.8×0.016MDGA2
regulation of neurotransmitter receptor localization to postsynaptic specialization membrane1126.7×0.016GPC6
establishment of endothelial barrier1109.4×0.018PDE4D
positive regulation of heart rate1100.3×0.018PDE4D
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum196.3×0.018PDE4D
negative regulation of cAMP/PKA signal transduction186.0×0.019PDE4D
regulation of heart rate166.9×0.022PDE4D
positive regulation of interleukin-2 production166.9×0.022PDE4D
positive regulation of interferon-beta production156.0×0.025ARRDC4
cellular response to cAMP141.5×0.033PDE4D
regulation of signal transduction138.2×0.033GPC6
protein K63-linked ubiquitination138.2×0.033ARRDC4
positive regulation of type II interferon production132.1×0.038PDE4D
modulation of chemical synaptic transmission126.2×0.044NXPH1
T cell receptor signaling pathway121.7×0.051PDE4D
cell migration18.8×0.119GPC6

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
PregabalinPhase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 6

Druggability breadth: 1 of 7 evidence-associated genes (14%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
PDE4DINAMRINONE

Top cohort targets by molecule count

SymbolMoleculesMax phase
PDE4D2694
NKAIN200
MDGA200
NXPH100
ARRDC400
TMPRSS900
GPC600

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
INAMRINONE4PDE4D
THEOPHYLLINE4PDE4D
VARDENAFIL4PDE4D
MILRINONE4PDE4D
LOSARTAN4PDE4D
SILDENAFIL4PDE4D
ROFLUMILAST4PDE4D
ENOXIMONE4PDE4D
ENSIFENTRINE4PDE4D
CRISABOROLE4PDE4D
APREMILAST4PDE4D
PENTOXIFYLLINE4PDE4D
TADALAFIL4PDE4D
DIPYRIDAMOLE4PDE4D
CANDESARTAN CILEXETIL4PDE4D
TELMISARTAN4PDE4D
SIMVASTATIN4PDE4D
MORICIZINE4PDE4D
AMLEXANOX4PDE4D
AMOXAPINE4PDE4D
PONATINIB4PDE4D
RUCAPARIB4PDE4D
CELECOXIB4PDE4D
VILANTEROL4PDE4D
TIOCONAZOLE4PDE4D
UNOPROSTONE ISOPROPYL4PDE4D
OLMESARTAN MEDOXOMIL4PDE4D
HYDROXYPROGESTERONE CAPROATE4PDE4D
NORGESTIMATE4PDE4D
THIOTHIXENE4PDE4D

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
PDE4D863Binding:805, Functional:33, ADMET:23, Toxicity:2

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
PDE4D3.1.4.533’,5’-cyclic-AMP phosphodiesterase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
PDE4D863

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
INAMRINONE4PDE4D
THEOPHYLLINE4PDE4D
VARDENAFIL4PDE4D
MILRINONE4PDE4D
LOSARTAN4PDE4D
SILDENAFIL4PDE4D
ROFLUMILAST4PDE4D
ENOXIMONE4PDE4D
ENSIFENTRINE4PDE4D
CRISABOROLE4PDE4D
APREMILAST4PDE4D
PENTOXIFYLLINE4PDE4D
TADALAFIL4PDE4D
DIPYRIDAMOLE4PDE4D
CANDESARTAN CILEXETIL4PDE4D
TELMISARTAN4PDE4D
SIMVASTATIN4PDE4D
MORICIZINE4PDE4D
AMLEXANOX4PDE4D
AMOXAPINE4PDE4D
PONATINIB4PDE4D
RUCAPARIB4PDE4D
CELECOXIB4PDE4D
VILANTEROL4PDE4D
TIOCONAZOLE4PDE4D
UNOPROSTONE ISOPROPYL4PDE4D
OLMESARTAN MEDOXOMIL4PDE4D
HYDROXYPROGESTERONE CAPROATE4PDE4D
NORGESTIMATE4PDE4D
THIOTHIXENE4PDE4D

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1PDE4D
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug2MDGA2, TMPRSS9
EDifficult family or no structure, no drug4NKAIN2, NXPH1, ARRDC4, GPC6

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
MDGA20PDE4D
NKAIN20—
NXPH10—
ARRDC40—
TMPRSS90—
GPC60—

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified5
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00269594PHASE2COMPLETEDAn Open-Label Study Of Lamictal In Neurotic Excoriation
NCT07017543Not specifiedACTIVE_NOT_RECRUITINGDynamics of Psychotherapy and Treatment Outcomes
NCT02257996Not specifiedUNKNOWNEffectiveness of Online Systematic Brief Psychodynamic Psychotherapy for Neurotic Disorders: Randomized Controlled Trial
NCT02308462Not specifiedCOMPLETEDImplementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents
NCT02721316Not specifiedCOMPLETEDOutpatient Nurse Monitoring Under the Prevention of Recurrent Suicidal
NCT03904784Not specifiedTERMINATEDSchool Withdrawal in Adolescents

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
LAMOTRIGINE41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 71

This page pulls from 71 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot